Saundra Buys, MD, medical oncologist at Huntsman Cancer Institute (HCI) and a professor of medicine at the University of Utah was named by Forbes among the top breast cancer physicians in the country. Buys is one of only 27 in the nation to receive this recognition.
Office of Public Affairs
2000 Circle of Hope,
Salt Lake City, UT 84112
Each year over 1,000 adolescents and young adults (AYAs) in Utah are diagnosed with cancer. For many of these young adults (ages 15-39), the cancer diagnosis is their first real medical issue. Patients may suddenly have to learn the difference between a medical oncologist and a radiation oncologist. They may also have questions about fertility issues, or need help understanding the complexities of the healthcare system. To help guide patients through these tough issues Huntsman Cancer Institute (HCI) at the University of Utah, in collaboration with Intermountain Healthcare, offers a patient navigator designed to meet the needs of AYA cancer patients.
Huntsman Cancer Institute Researchers Trace Timeline of Tumor Evolution in Metastatic Breast Cancer Patients
A new study by researchers at Huntsman Cancer Institute (HCI) at the University of Utah observed how breast cancer tumors evolve over time and demonstrated how changes within tumors may contribute to the process by which cancers no longer respond to treatment. Further, the research identifies that some of these changes may be shared across certain treatment-resistant breast cancers. The study was published this month in Nature Communications.
Risk for aging-related diseases such as heart disease and diabetes was significantly higher among thyroid cancer survivors in Utah than it was among age-matched, cancer-free individuals, with those diagnosed before age 40 having the highest risk for some of the diseases, according to results published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research
All cancer treatments and medications that are used today, at one point, were clinical trials. Clinical trials can offer hope, particularly in a complex disease like cancer. But getting access to clinical trials can be difficult, especially if patients have to travel a long distance to a hospital that offers trials.
Huntsman Cancer Institute Study Identifies Enhanced Impact of Treatment for Hereditary Cancer Patients
People with an inherited syndrome called familial adenomatous polyposis (FAP) have a 100% lifetime risk of developing colorectal cancer if they do not seek appropriate medical care. Recent findings published by researchers at Huntsman Cancer Institute at the University of Utah identified a promising prevention treatment for patients with FAP.
When she was first diagnosed with ovarian cancer, Dr. Jan Byrne didn't know of any survivors of the disease. "It's a devastating disease — a silent killer," she said. "A lot of people don't make it." Byrne's cancer was found in the early stages, however, and after six months of chemotherapy and three major surgeries at Huntsman Cancer Institute, she survived. It's been six years.
A study published today in Cell Systems highlights a new research method using the recently developed CRISPR technique. In short, CRISPR is a technology that allows researchers to cut out a section of DNA that causes a disease, like cancer, and then replace the section with normal, healthy genes.
The results of a national cancer survey find a significant number of childhood cancer survivors are worried about keeping their health insurance, to the point of letting it affect their career decisions. The findings were published today in JAMA Oncology. Anne Kirchhoff, PhD, investigator at Huntsman Cancer Institute (HCI) at the University of Utah and assistant professor of pediatrics, led the study. Her goal was to examine the prevalence of job lock in full-time, employed childhood cancer survivors. Job lock is when an employee stays at a job in order to keep work-related health insurance.
Utah has had the nation's greatest incidence of melanoma from 2010 to 2014, the last year for which data is available. Its rates of melanoma have more than doubled in the past 17 years, from 20 to 42 cases for every 100,000 people, according to the Utah Department of Health and the Utah Cancer Registry.
New research from scientists at Huntsman Cancer Institute (HCI) at the University of Utah and collaborators at University of Utah Health (U of U Health) sheds light on the complex process that occurs in the development of human sperm stem cells. This is the first study to characterize the changes human sperm stem cells undergo as they mature. The results have implications for understanding male infertility as well as cancer development and were published today in the journal Cell Stem Cell.
Huntsman Cancer Institute (HCI) at the University of Utah has announced David Gaffney, MD, PhD, as Senior Director for Clinical Research. In this position, Gaffney oversees HCI’s clinical research efforts which include more than 200 active clinical cancer trials at any given time.
Tumor-destroying vaccines have emerged as a new weapon in the fight against cancer. Conventional vaccines prevent people from getting sick in the first place. Now scientists are testing a new type of vaccine that treats existing cancers by spurring immune cells to go on the attack. These drugs—known as therapeutic vaccines—hold the potential to plunge cancers into remission without causing the side effects of treatments such as chemotherapy.
Review indicates need to further explore relationship between fat and cancer. Adipose tissue, or fat, may influence the development of cancer in diverse ways, depending on the type of fat and the location in the body, according to results of a systematic review published in Cancer Prevention Research, a journal of the American Association for Cancer Research
Religious young women are less knowledgeable about a vaccine that guards against several different types of cancer, suggests a new study from Utah.
With eyes to the sky and smiles that mirror the partial eclipse, hundreds of patients, doctors, nurses, and staff watched the celestial phenomenon from the patio of the Huntsman Cancer Institute.
Mrs. Cándida Montilla de Medina, First Lady of the Dominican Republic, and her delegation visited Huntsman Cancer Institute (HCI) at the University of Utah yesterday, Thursday, August 10. During her visit, Mrs. Montilla de Medina toured HCI and met with physicians, researchers, Elder Ronald A. Rasband of The Church of Jesus Christ of Latter-day Saints, and members of the Huntsman family, including Jon M. Huntsman, Sr., to learn about HCI’s mission: to research cancer from its beginnings, develop new cancer treatments, and relieve the suffering of cancer patients.
Huntsman Cancer Institute (HCI) at the University of Utah is the first cancer center in the United States to use a new, state-of-the-art CT scanner that allows doctors to view higher quality, personalized images of a patient’s tumor. The scanner, called the Somatom Confidence 64 from Siemens, boasts numerous features that create more detailed images, giving physicians the ability to direct their therapy precisely where it’s needed.
Study Shows Shorter Course of Radiation May Be a Safe and Convenient Option for Breast Cancer Patients after Mastectomy
Research published in the Journal of Clinical Oncology demonstrates that a shorter course of radiation may be a good option for breast cancer patients who need radiation following mastectomy. The Phase II clinical trial examined the safety of treating women with a three-week course of radiation instead of the traditional six weeks.
he Huntsman Cancer Institute, respected worldwide for its medical treatment of patients, also offers Chinese practices of deep breathing, meditation and gentle movement to help patients with recovery.
Our media relations representatives are here to help reporters Monday-Friday, 7:30 am-5 pm.
Public Affairs Manager
Public Relations Associate
After-hours calls: Reporters calling before or after business hours on an urgent matter can page the University of Utah Health on-call media relations representative at 801-581-7387 and press 1.